Simplifying Fibromyalgia Assessment: The VASFIQ Brief Symptom Scale

Area of Science:

• Rheumatology
• Clinical Assessment
• Pain Management

Background:

• Fibromyalgia is a complex chronic condition characterized by widespread pain, fatigue, sleep disturbances, and mood disorders.
• Accurate assessment of disease severity and symptom burden is crucial for effective management.
• Existing assessment tools can be lengthy, posing challenges for rapid clinical evaluation.

Purpose of the Study:

• To evaluate the Visual Analog Scale for Fibromyalgia Impact Questionnaire (VASFIQ) for quantifying fibromyalgia global disease severity.
• To determine the VASFIQ's ability to identify patients with significant symptoms of fatigue, poor sleep, depression, or anxiety.
• To establish validated cutoff scores for the VASFIQ in identifying clinically significant symptom levels.

Main Methods:

• Spearman rank correlations were used to compare VASFIQ scores with validated full-length questionnaires for fatigue, sleep, depression, and anxiety.
• Data were analyzed from 2229 patients across three pregabalin fibromyalgia trials.
• Receiver operating characteristic (ROC) analyses determined VASFIQ cutoff scores for clinically significant symptoms.

Main Results:

• Global VASFIQ and Fibromyalgia Impact Questionnaire (FIQ) scores showed high correlations (ρ = 0.94–0.97).
• Individual VASFIQ components strongly correlated with corresponding validated symptom measures (e.g., VASfatigue with MAF-GFI, ρ = 0.64–0.76).
• Specific cutoff scores were identified for fatigue, sleep, depression, anxiety, and overall disease severity.

Conclusions:

• The VASFIQ scale provides a brief and accurate method for assessing fibromyalgia global severity.
• It effectively identifies patients experiencing significant fatigue, sleep disturbances, depression, or anxiety.
• The VASFIQ facilitates rapid patient assessment, supporting informed treatment decisions in clinical practice.